通过生物使用对结性脊髓炎患者bDMARDs的有效性:来自CorEvitas PsA/SpA注册表的经验
Philip J Mease1, Taylor Blachley2, William N Malatestinic3
1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.
Current medical research and opinion
|December 5, 2023
概括
许多性脊柱炎患者开始使用生物修饰性抗风湿药物 (bDMARDs) 后,无法达到最佳反应. 需要进一步的研究来了解影响AS患者治疗结果的因素.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 化脊柱炎 (AS) 是一种慢性炎症性疾病.
- 生物修饰性抗风湿药物 (bDMARDs) 用于管理AS.
- 在现实环境中理解治疗反应至关重要.
研究的目的:
- 根据先前的生物暴露,在AS患者中对bDMARD发起者的特征.
- 评估bDMARD开始后疾病活动和患者报告结果 (PRO) 的变化.
- 评估bDMARDs在美国AS患者中的实际有效性.
主要方法:
- 从CorEvitas牛皮关节炎/脊柱性关节炎注册表对AS患者的回顾性分析.
- 纳入标准:年龄≥18岁,医生诊断AS,入学时间为2013年3月至2019年11月.
- 收集的数据:基线人口统计数据,并发症,疾病特征,治疗方法和PROs. 分析6个月和12个月的反应率和变化.
主要成果:
- 在313个AS bDMARD启动中,有179个有6个月的随访数据.
- 在6个月后,ASAS20/40实现率为20.1%/14.0%,只有34%的人实现了低疾病活性 (ASDAS <2.1).
- 与生物经验丰富的患者 (21.4%/7.4%) 相比,从未有过生物经验的患者显示出更高的ASAS20/40率 (26.2%/14.7%).
结论:
- 开始服用bDMARD的AS患者往往表现出不理想的治疗反应.
- 很大一部分患者没有达到低疾病活性.
- 需要进一步调查,以确定与bDMARDs不充分改善和治疗反应相关的因素.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
01:29Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121